Clinical Trial

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Study acronym: Optimum 2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Metformin Monotherapy or in Combination with Sodium-dependent Glucose Transporter 2 (SGLT2) Inhibitors or Sulfonylureas
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-12.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-20
Trial Details
NCT Number NCT06778967
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 1,100 participants
Start Date 2025-02-13
Primary Completion 2026-12-11 (estimated)
Study Completion 2026-12-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-25